

CURRICULUM VITAE



Name: David Augustus Fiellin, M.D.

Date of Birth: January 26, 1961

Place of Birth: Hanover, New Hampshire

Office Address: Yale University School of Medicine
333 Cedar Street
P.O. Box 208025
New Haven, CT. 06520-8025
Telephone: 203-688-2984 email: david.fiellin@yale.edu

Home Address: 165 Cold Spring Street
New Haven, Ct. 06511

Current Position: Associate Professor of Medicine,
Yale University School of Medicine

Education

1979-1983 Earlham College, Richmond, Indiana, B.A.

1987-1991 Emory University School of Medicine, Atlanta, Georgia, M.D.

Postgraduate

1991-1994 Intern, Junior, and Senior Resident in Internal Medicine, Yale-New Haven Hospital, New Haven, Connecticut

1994-1995 Chief Resident, Yale-New Haven Hospital and West Haven Veterans Affairs Medical Center, New Haven and West Haven, Connecticut

1995-1997 Postdoctoral Fellow, The Robert Wood Johnson Clinical Scholars Program, Yale University, New Haven, Connecticut

Academic Appointments

1994-1995 Instructor in Medicine, Yale University School of Medicine, New Haven, Connecticut

1997-2002 Assistant Professor of Medicine, Yale University School of
Medicine, New Haven, Connecticut

2002-Present Associate Professor of Medicine, Yale University School of
Medicine, New Haven, Connecticut

Career

1984-1987 Staff Research Associate, General Clinical Research Center,
University of California, San Francisco, San Francisco, California

1988-1989 Student Intern, Clinical Research Center, Emory University School
of Medicine, Atlanta, Georgia

Publications

1. Bonkovsky H, **Fiellin D**, Smith G, Slaker D, Simon D, Galambos J. A randomized controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. *American Journal of Gastroenterology* 1991; 86:1200-8.
2. Bonkovsky H, Singh R, Jafri I, **Fiellin D**, Smith G, Simon D, Cotsonis G, Slaker D. A randomized controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance and nutrition. *American Journal of Gastroenterology* 1991; 86:1209-18.
3. **Fiellin DA**, Feinstein AR. Bootstraps and Jackknives: New, computer-intensive statistical tools that require no mathematical theories. *Journal of Investigative Medicine* 1998; 46:22-26.
4. **Fiellin DA**, Samet JH, O'Connor PG. Reducing bias in observational research on alcohol withdrawal syndrome. *Substance Abuse* 1998; 19:23-31.
5. Reid MC, **Fiellin DA**, O'Connor, PG. Hazardous and harmful alcohol consumption in primary care. *Archives of Internal Medicine* 1999; 159:1681-1689.
6. **Fiellin DA**, Saitz R. Alcohol problems: Screening and management in the primary care setting. *Primary Care Case Reviews* 1999; 2:133-144.
7. **Fiellin DA**, Schottenfeld RS. Office-based opioid treatment. *Proceedings of the Tenth Annual Meeting and Symposium of the American Academy of Addiction Psychiatry* 1999;34-5.
8. **Fiellin DA**, Reid MC, O'Connor PG. New therapies for patients with alcohol problems: Application to primary care. *American Journal of Medicine* 2000; 108:227-237.
9. **Fiellin DA**, Concato J. Beyond diagnosis: Patient mix and challenges to patient care in ambulatory training sites. *The American Journal of the Medical Sciences* 2000; 319:106-110.
10. Reid MC, Voynick IM, Peduzzi P, **Fiellin DA**, Tinetti ME, Concato J. Alcohol exposure and health services utilization in older veterans. *Journal of Clinical Epidemiology* 2000; 53:87-93.
11. O'Connor PG, **Fiellin DA**. Pharmacologic treatment of heroin-dependent patients. *Annals of Internal Medicine* 2000; 133: 40-54.
12. **Fiellin DA**, Reid MC, O'Connor, PG. Screening for alcohol problems in primary care: A systematic review. *Archives of Internal Medicine* 2000; 160:1977-1989.

13. Holmboe ES, **Fiellin DA**, Cusanelli E, Remetz M, Krumholz HM. Perceptions of benefit and risk of patients undergoing first-time elective percutaneous coronary revascularization. *Journal of General Internal Medicine* 2000; 15: 632-7.
14. **Fiellin DA**, Reid MC, O'Connor PG. Outpatient management of patients with alcohol problems. *Annals of Internal Medicine* 2000; 133: 815-27.
15. **Fiellin DA**, Storti SA, Schottenfeld RS, Biscoe JD, Pantalon MV, O'Connor PG (2000). Methadone Medical Maintenance: A training and resource guide for office-based physicians. Addiction Technology Transfer Center of New England, Providence.
16. Brewer PA, **Fiellin DA**. Reporting impaired drivers to the emergency department – A success story. *Developing Best Practices of Emergency Care for the Alcohol-Impaired Patient: Recommendations from the National Conference, 2000*; 11-12.
17. D'Onofrio G, Degutis LC, **Fiellin DA**, Pantalon, MV. Screening and brief intervention for alcohol problems in the emergency department. *Developing Best Practices of Emergency Care for the Alcohol-Impaired Patient: Recommendations from the National Conference, 2000*; 15-17.
18. Sindelar JL, **Fiellin DA**. Innovations in treatment for drug abuse: Solutions to a public health problem. *Annual Review of Public Health* 2001; 22: 249-272.
19. **Fiellin DA**. Review of "Community treatment of drug misuse: more than methadone" *Addiction* 2001; 96:342-3.
20. **Fiellin DA**, Rosenheck RA, Kosten, TR. Office based treatment for opiate dependence: Reaching new patient populations. *American Journal of Psychiatry* 2001; 158: 1200-1204.
21. **Fiellin DA**, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. *JAMA* 2001;286:1724-1731.
22. **Fiellin DA**, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld R. Treatment of heroin dependence with buprenorphine in primary care. *American Journal of Drug and Alcohol Abuse* 2002;28(2):231-241.
23. **Fiellin DA**. Training physicians in the use of buprenorphine. *National Institute on Drug Abuse Research Monograph Series. Problems of Drug Dependence, 2001: Proceedings of the 63rd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. 2002:33-34. NIH Publication No. 02-5097.*
24. **Fiellin DA**, O'Connor PG, Holmboe ES, Horwitz RI. Risk for delirium tremens in patients with alcohol withdrawal syndrome. *Substance Abuse* 2002;23(2):83-94.
25. **Fiellin DA**, O'Connor PG. Office-based treatment of opioid dependent patients. *New England Journal of Medicine* 2002;347(11):817-823.
26. **Fiellin DA**, Butler R, D'Onofrio G, Brown RL, O'Connor PG. The physician's role in caring for patients with substance use disorders: Implications for medical education and training. *Substance Abuse* 2002;23(3):(suppl) 207-212.
27. Potenza MN, **Fiellin DA**, Heninger GR, Rounsaville BJ, Mazure CM. Gambling: An addictive behavior with health and primary care implications. *Journal of General Internal Medicine* 2002;17:721-732.
28. **Fiellin DA**, O'Connor PG. New Federal initiatives to enhance the medical treatment of opioid dependence. *Annals of Internal Medicine* 2002;137:688-692.

29. Fiellin DA, Kosten TR. Office based treatment of opiate dependent patients with buprenorphine. Web-based training course for American Psychiatric Association 2002. Available at: <http://www.psych.org/cme/apacme/index.cfm>.
30. **Fiellin DA**, Rosenheck RA, Kosten, TR. Coordination of medical care and opioid dependence treatment in primary care: A case report. *Substance Abuse* 2003;24:43-46.
31. **Fiellin DA**, Lintzeris N. Methadone syrup injection in Australia: a sentinel finding? *Addiction* 2003;98:385-386.
32. **Fiellin DA**, Degutis LC, D'Onofrio G. Traumatic injuries related to alcohol and other drug use. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. *Principles of Addiction Medicine Third Edition*. Maryland: American Society of Addiction Medicine, Inc. 2003;1195-1204.
33. Wong JG, Kraus ML, Feinberg MA, **Fiellin DA**. Providing opioid agonist maintenance therapy in a generalist's office: The physician's perspective. *Substance Abuse (Editorial)* 2003;24(1):1-3.
34. Kraus ML, O'Connor PO, Babor TF, Brunell RJ, **Fiellin DA**, Holmboe E, Kirk TA, Leone P. Connecticut Statewide Addiction Medicine/Psychiatry Grand Rounds. *Connecticut Medicine* 2003;67:357-358.
35. O'Connor PG, **Fiellin DA**. Primary Healthcare Settings. In: Johnson BA, Ruiz P, Galanter M, eds. *Handbook of Clinical Alcoholism Treatment*. Baltimore: Lippincott Williams Wilkins, 2003;166-173.
36. **Fiellin DA**, O'Connor PG. Alcohol abuse. <http://www.pier.acponline.org/physicians/diseases/d282/d282.html>. [Date accessed: 2003 Nov 17] In: PIER [online database]. Philadelphia, American College of Physicians, 2003.
37. **Fiellin DA**, Barthwell AG. Guideline development for office-based pharmacotherapies for opioid dependence. *Journal of Addictive Diseases* 2003;22:109-20.
38. Sullivan LE, **Fiellin DA**. Hepatitis C and HIV infections: implications for clinical care in injection drug users. *American Journal on Addictions* 2004;13:1-20.
39. Kosten TR, **Fiellin DA**. Buprenorphine for office-based practice: consensus conference overview. *American Journal on Addictions* 2004;13(suppl 1):S1-S7.
40. **Fiellin DA**, O'Connor PG, Chawarski M, Schottenfeld, RS. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. *American Journal on Addictions* 2004;13(suppl 1):S67-S78.
41. Pantaloni MV, **Fiellin DA**, O'Connor PG, Chawarski M, Pakes J, Schottenfeld RS. Counseling requirements for buprenorphine maintenance in primary care: Lessons learned from a preliminary study in a methadone maintenance program. *Addictive Disorders and Their Treatment* 2004;3:71-76.
42. **Fiellin DA**, Substance use disorders in HIV-infected patients: impact and new treatment strategies. *Topics in HIV Medicine* 2004;12:77-82.
43. **Fiellin DA**, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. *Journal of Substance Abuse Treatment* 2004;27:153-159.
44. Wong JG, Holmboe ES, Jara GB, Martin J, Becker WC, **Fiellin DA**. Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence. *Substance Abuse* 2005;25(4):35-40.

45. Sullivan LE, Metzger DS, Fudala PJ, **Fiellin DA**. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. *Addiction* 2005;100:150-158.
46. Gordon AJ, Conigliaro J, **Fiellin DA**. Selective methods used in alcohol research: screening in primary care-methods and approaches. In: Preedy VR, Ronald R, eds. *Comprehensive Handbook of Alcohol Related Pathology* 2005:1327-1345.
47. Inouye SK, **Fiellin DA**. An evidence-based guide to writing grant proposals for clinical research. *Annals of Internal Medicine* 2005;142:274-282.
48. D'Onofrio G, Pantalon MV, Degutis LC, **Fiellin DA**, O'Connor PG. Development and implementation of an emergency practitioner-performed brief intervention for harmful and hazardous drinkers in the emergency department. *Academic Emergency Medicine* 2005;12:249-256.
49. Sullivan LE, **Fiellin DA**, O'Connor PG. The prevalence and impact of alcohol problems in major depression: A systematic review. *The American Journal of Medicine* 2005;118:330-341.
50. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, **Fiellin DA**. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? *Drug and Alcohol Dependence* 2005;79:113-116.
51. **Fiellin, DA**. New Treatment Strategies for Opioid Dependence. *Connecticut Medicine*, April, 2005;69(4):224.
52. Brown KE, Levine JM, **Fiellin DA**, O'Connor P, Sledge WH. Primary intensive care: pilot study of a primary care based intervention for high utilizing patients. *Journal of Disease Management* 2005;89(3):169-77.
53. Sullivan LE, **Fiellin DA**. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV infected patients with opioid dependence. *Clinical Infectious Diseases* 2005;41(6):891-6.
54. **Fiellin DA**, Strain EC. Office-based treatment with buprenorphine and other medications. In: Strain EC, Stitzer MI, eds. *The Treatment of Opioid Dependence*. Baltimore: The Johns Hopkins University Press, 2005:251-276.
55. Becker WC, **Fiellin DA**. Provider satisfaction with office-based treatment of opioid dependence: A systematic review. *Substance Abuse* 2006;(1)26:15-22.
56. **Fiellin DA**, O'Connor PG, Wang Y, Radford MJ, Krumholz HM. Quality of care for acute myocardial infarction in elderly patients with alcohol-related diagnoses. *Alcoholism: Clinical and Experimental Research* 2006;30:70-75.
57. **Fiellin DA**. Buprenorphine: Effective treatment of opioid addiction starts in the office. *American Family Physician*. 2006;73(9):1513-4.
58. Kraemer KL, McGinnis KA, Skanderson M, Cook R, Gordon A, Conigliaro J, Shen Y, **Fiellin DA**, Justice AC. Alcohol problems and health care services use in HIV-positive and HIV-negative veterans. *Medical Care* 2006;44: S44-S51
59. Mehra R, Moore BA, Crothers K, Tetrault J, **Fiellin DA**. The association between marijuana smoking and lung cancer: A systematic review. *Archives of Internal Medicine* 2006; 166(13):1359-67.
60. **Fiellin DA**, Pantalon MV, Chawarski M, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld R. Counseling for Buprenorphine-Naloxone Maintenance Treatment in Primary Care. *New England Journal of Medicine* 2006; 355(4): 365-374.

61. Sullivan LE, Tetrault J, Bangalore D, **Fiellin DA**. Training HIV physicians to prescribe buprenorphine for opioid dependence. *Substance Abuse* 2006 (in press).
62. Gunderson EW, **Fiellin DA**, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in person training in the use of buprenorphine. *Substance Abuse* (in press).
63. **Fiellin DA**, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale and efficacy of existing and new treatments. *Clinical Infectious Diseases* (in press)
64. Sullivan LE, Bruce RD, Haltiwanger D, Lucas GE, Eldred L, Finkelstein R, **Fiellin DA**. Initial strategies for integrating buprenorphine into HIV care settings in the United States. *Clinical Infectious Diseases* (in press).
65. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantaloni MV, O'Connor PG, Schottenfeld RS, **Fiellin DA**. A trial of integrated buprenorphine/naloxone and HIV clinical care. *Clinical Infectious Diseases* (in press).

Letters to the Editors

66. **Fiellin DA**, Feinstein AR. Bootstraps and Jackknives: New, computer-intensive statistical tools that require no mathematical theories (Letter to Editor). *Journal of Investigative Medicine* 1998;46:274.
67. **Fiellin DA**, Reid MC, O'Connor PG. An automated screening strategy to identify patients with alcohol problems in a primary care setting (Letter to Editor). *Archives of Internal Medicine* 2001;161:895-896.
68. O'Connor PG, **Fiellin DA**. Pharmacologic treatment of heroin-dependent patients (Letter to Editor). *Annals of Internal Medicine* 2001;134:714-715.
69. **Fiellin DA**, Reid MC, O'Connor PG. Outpatient management of patients with alcohol problems (Letter to Editor). *Annals of Internal Medicine* 2001;135:241.
70. **Fiellin DA**, O'Connor PG. Office-based treatment of opioid-dependent patients (Letter to Editor). *New England Journal of Medicine* 2002;348:81-82.

Abstracts

Portale AA, Al-Bander HA, Halloran BP, **Fiellin D**, Morris RC Jr. Restriction of dietary phosphorous does not increase serum 1,25-(OH)₂D in the normal dog. *Kidney International* 1990; 37:469.

Fiellin DA, Concato J. Beyond diagnosis: Clinical and functional characteristics of patients in ambulatory clinics staffed by Internal Medicine residents. *Journal of Investigative Medicine* 1996; 44:409A.

Fiellin DA, O'Connor PG, Holmboe ES, Horwitz RI. Predicting risk for alcohol withdrawal delirium. *Journal of Investigative Medicine* 1997; 45:198A.

Fiellin DA, Hickey LB, Concato J. Beyond diagnosis: Patient mix and challenges to patient care in ambulatory training sites. *Journal of General Internal Medicine* 1997; 12 Suppl 1:90.

Fiellin DA, Saitz R, O'Connor PG. Prognosis in alcohol withdrawal: Are current methods providing valid evidence? *Journal of General Internal Medicine* 1998; 13 Suppl 1:18.

Brown KE, Horton LE, **Fiellin DA**, O'Connor PG. Improving asthma care in a general medicine teaching clinic: Results of a quality improvement intervention. *Journal of General Internal Medicine* 1998; 13 Suppl 1:44.

Fiellin D, O'Connor P, Wang Y, Krumholz H. Alcohol-related diagnoses are not a barrier to quality care in elderly patients with acute myocardial infarction. *Journal of General Internal Medicine* 1999; 14 Suppl 2:28.

Fiellin DA, Pantalon MP, Pakes JP, O'Connor PG, Chawarski M, Kelly KP, Schottenfeld RS. Primary care treatment of opioid dependence with buprenorphine. (Oral Presentation at College on Problems of Drug Dependence, June 12-17, 1999)

Pantalon MP, Chawarski M, Pakes JP, **Fiellin DA**, Schottenfeld RS. Counseling requirements for buprenorphine maintenance: A pilot study. *NIDA Research Monograph* 2000; 180: 163.

McKenzie KC, **Fiellin DA**, Hickey LB, Concato J. Challenging aspects of the patient-resident ambulatory encounter. *Journal of General Internal Medicine* 1999; 14 Suppl 2:145.

Brown KE, Levine JM, O'Connor PG, **Fiellin DA**, Sledge WH. Primary intensive care: Results of a clinic designed to care for high utilizing and difficult patients. *Journal of General Internal Medicine* 1999; 14 Suppl 2:89.

Fiellin DA Levine JM, Brown KE, Chawarski M, O'Connor PG, Sledge WH. Primary care patients with high utilization of inpatient services: Predicting mortality. *Journal of General Internal Medicine* 2000; 15 Suppl 1:66.

Fiellin DA, Levine JM, Brown KE, Sledge WH, O'Connor PG. Substance use and psychiatric disorders in primary care patients with high utilization of inpatient services. *Journal of General Internal Medicine* 2000; 15 Suppl 1:66.

Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care: A systematic review. *Journal of General Internal Medicine* 2000; 15 Suppl 1:65.

Levine JM, Brown KE, Chawarski M, **Fiellin D**, O'Connor PG, Sledge WH. The impact of major depression in a cohort of high-utilizing primary care patients. *Journal of General Internal Medicine* 2002;17 Suppl 1:115.

Reid MC, **Fiellin DA**, Chandrasena AR, O'Connor PG. Implementation of an opioid contract policy in a primary care setting. *Journal of General Internal Medicine* 2002;17 Suppl 1:118.

Brown KE, **Fiellin DA**, Chawarski MC, White W, Sledge WH, O'Connor PG, Levine J. A randomized trial of primary intensive care to reduce hospital admissions in high utilizers. *Journal of General Internal Medicine* 2002;17 Suppl 1:121.

Sullivan LE, O'Connor PG, Schottenfeld RS, **Fiellin DA**. Office-based treatment of opioid dependence: clinical challenges and opportunities for generalists. *Journal of General Internal Medicine* 2002;17 Suppl 1:169.

Fiellin DA, O'Connor PG, Chawarski M, Pantalon MP, Schottenfeld RS. Office versus narcotic treatment program-based buprenorphine for opioid dependence. *Drug and Alcohol Dependence* 2002;66 Suppl 1:S55-6.

Sullivan LE, **Fiellin DA**, Durante AJ, Sofair AN. The impact of substance use disorders on eligibility for treatment of hepatitis C infection. *Journal of General Internal Medicine* 2003;18 Suppl 1:158.

Sullivan, LE, **Fiellin DA**, O'Connor PG. The prevalence and impact of alcohol problems in major depression: A systematic review. *Journal of General Internal Medicine* 2004; 19 Suppl 1:223.

Sullivan, LE, Moore, BA, Chawarski MC, Schottenfeld RS, O'Connor, PG, **Fiellin, DA**. Buprenorphine reduces HIV risk behaviour among opioid dependent patients in primary care. *Journal of General Internal Medicine*, 2005;20 Suppl 1:172.

Fiellin, DA, Pantalon, MV, Chawarski MC, Sullivan, LE, Barry D, O'Connor, PG, Schottenfeld, RS. Counseling and attendance requirements for buprenorphine treatment in primary care. *Journal of General Internal Medicine*, 2005;20 Suppl 1:173.

Sullivan LE, Tetrault J, Bangalore D, **Fiellin, DA**. HIV physicians' preparedness to prescribe buprenorphine for opioid addiction. *Journal of General Internal Medicine*, 2005;20 Suppl 1:177.

Chwastiak, LA, Goulet J, Bryant KJ, Conigliaro J, Crystal S, Day NL, **Fiellin DA**, O'Connor PG, Rimland D, Rodriguez-Barradas M, Justice AC. Prescribing patterns of opioid pain medications and benzodiazepines among HIV+ and HIV- patients in the national VA system. *Journal of General Internal Medicine*, 2005;20 Suppl 1:179.

Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, **Fiellin DA**. Effects of marijuana on pulmonary function: a systematic review. *Journal of General Internal Medicine* 2006;21 Suppl 4:47.

Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, **Fiellin DA**. Opioid treatment for chronic back pain: a systematic review and meta-analysis of its prevalence efficacy and association with addiction. *Journal of General Internal Medicine* 2006;21 Suppl 4:93.

Becker WC, Desai RA, Tetrault JM, Sullivan LE, **Fiellin DA**. Identifying risk factors associated with non-medical prescription opioid use: results from a national survey. *Journal of General Internal Medicine*, 2006;21 Suppl 4:68.

Tetrault JM, Desai RA, Becker WC, **Fiellin DA**, Concato J, Sullivan LE. Risk factors associated with abuse of prescription opioids in women: results of a national survey. *Journal of General Internal Medicine*, 2006;21 Suppl 4:126.

Fiellin DA, O'Connor PG, Chawarski M, Pantalon MP, Schottenfeld RS. Sustained abstinence and early urine toxicology analyses in office-based buprenorphine treatment. *Drug and Alcohol Dependence* (submitted).

Lectures/Seminars

Presenter, Management of alcohol problems in general internal medicine practice, April 25, 1998, Society of General Internal Medicine Annual Meeting, Chicago, Illinois

Faculty member, Reducing substance abuse in the clinic and community, April 23, 1998, Society of General Internal Medicine Annual Meeting, Chicago, Illinois

Presenter, Ambulatory detoxification from alcohol, April 30, 1999, Society of General Internal Medicine Annual Meeting, San Francisco, California

Presenter, Office-based opioid treatment, December 3, 1999, American Academy of Addiction Psychiatry Annual Meeting, Nassau, Bahamas

Presenter, Integrating medical and behavioral health care: Primary Intensive Care, April 1, 2000, Yale Conference on Behavioral Health: Integrating Care, Mashantucket, Connecticut

Moderator and Presenter, Are we making the best use of the existing pharmacotherapies? Expanding office-based physician therapies may be one solution. April 8, 2000, American Methadone Treatment Association Annual Conference, San Francisco, California

Presenter, Methadone maintenance in primary care: Three models. April 11, 2000, American Methadone Treatment Association Annual Conference, San Francisco, California

Presenter, Office-based medical maintenance in a network of primary care practitioners. November 6, 2000. Effective medical treatment of heroin addiction in office-based practices with a focus on methadone maintenance, Sponsored by Physician Leadership on National Drug Policy (PLNDP). New York, New York

Presenter, Methadone maintenance in primary care. The Connecticut Medical Maintenance Project, November 10, 2000, Robert Wood Johnson Clinical Scholars Program National Meeting, Fort Lauderdale, Florida

Presenter, Screening, motivational interviewing and brief intervention for patients with alcohol problems in primary care. November 14, 2000, Hanley-Hazelden Foundation, West Palm Beach, Florida

Faculty Instructor, Buprenorphine Physician Training Course, December 9, 2000, American Academy of Addiction Psychiatry Annual Meeting, Phoenix, Arizona

Faculty Instructor, Buprenorphine Physician Training Course, Train the Trainers, March 8, 2001, California Society of Addiction Medicine, San Francisco, California

Presenter, Guidelines for Medical Methadone Maintenance and Office Based Practice, March 13, 2001, Best Practices: Treatment of Opiate Dependence, Newport, Rhode Island

Faculty Instructor, Buprenorphine Physician Training Course, March 14, 2001, Best Practices: Treatment of Opiate Dependence, Newport, Rhode Island

Faculty Instructor, Buprenorphine in Office-based treatment of opiate dependence, April 22, 2001, Annual Medical-Scientific Conference, American Society of Addiction Medicine, Los Angeles, California

Faculty Instructor, Office-based treatment of opiate dependence, May 6, 2001, American Psychiatric Association, New Orleans, Louisiana

Grand Rounds in Psychiatry, Office-based treatment of opioid dependent patients, May 29, 2001 Bronx-Lebanon Hospital, New York, New York

Presenter, Training physicians in the use of buprenorphine, June 18, 2001, College on Problems of Drug Dependence Annual Scientific Meeting, Scottsdale, Arizona

Presenter, Medically assisted withdrawal from methadone: Who, what and when. October 6, 2001. American Methadone Treatment Association Conference 2001, St. Louis, Missouri

Course Director and Faculty Instructor, Buprenorphine in office-based treatment of opioid dependence. October 6, 2001. American Methadone Treatment Association Conference 2001, St. Louis, Missouri

Faculty Instructor, Office-based buprenorphine treatment, October 13, 2001. American Psychiatric Association, Institute on Psychiatric Services, Orlando, Florida

Faculty Instructor, Buprenorphine in Office-based treatment of opioid dependence, November 4, 2001, American Society of Addiction Medicine State of the Art Conference, Washington, D.C.

Plenary Speaker, Office-based treatment of opioid dependence with buprenorphine, November 8, 2001, Association for Medical Education and Research on Substance Abuse National Conference, Alexandria, Virginia

Course Director and Faculty Instructor, Office-based treatment of opioid dependence with buprenorphine, November 11, 2001, Association for Medical Education and Research on Substance Abuse National Conference, Alexandria, Virginia

Grand Rounds, Connecticut State Medical Society, Addiction Medicine/Psychiatry, Hospital of St. Raphaels, November 28, 2001 and December 20, 2002, New Haven, Connecticut

Faculty Instructor, Use of Buprenorphine in the pharmacologic management of opioid dependence, January 18, 2002, American Academy of Addiction Psychiatry, New York, New York

Presenter, Treatment of opioid dependence with buprenorphine in primary care, February 5, 2002, Johns Hopkins Bayview Medical Center, Behavioral Pharmacology Research Unit, Baltimore, Maryland

Grand Rounds, Screening and treatment of alcohol problems in primary care, February 7, 2002, Middlesex Hospital, Middletown, Connecticut.

Grand Rounds in Internal Medicine, Office-based treatment of opioid dependent patients, March 20, 2002, Rush Medical College, Chicago, Illinois

Faculty Instructor, Use of Buprenorphine in the pharmacologic management of opioid dependence, March 22, 2002, American Academy of Addiction Psychiatry, Boston, Massachusetts

Faculty Instructor, Office-based buprenorphine treatment, April 4, 2002, Black Psychiatrists of America, Inc. Detroit, Michigan

Grand Rounds, Division of Substance Abuse, Office-based treatment of opioid dependence, April 3, 2002, Albert Einstein College of Medicine, New York, New York

Course Director and Faculty Instructor, Buprenorphine and office-based treatment of opioid dependence, April 28, 2002, American Society of Addiction Medicine Annual Medical-Scientific Conference, Atlanta, Georgia

Presenter, Office-based treatment of opioid dependence, May 2, 2002, Society of General Internal Medicine Annual Meeting, Atlanta, Georgia

Faculty Instructor, Office-based treatment of opiate dependence, May 2, 2002, American Psychiatric Association, Philadelphia, Pennsylvania

Panelist, Buprenorphine Courses and web-based training activities, July 26, 2002, Centers for Substance Abuse Treatment Stakeholders Meeting, Bethesda, Maryland.

Presenter, Screening, motivational interviewing and brief intervention for patients with alcohol problems. September 12, 2002, Hazelden Foundation, New York, New York

Presenter, Physician education and training about substance use disorders, National Forum on Health Professional Education about Substance Use Disorders. September 19, 2002. Washington, D.C.

Faculty Instructor, Use of Buprenorphine in the pharmacologic management of opioid dependence, October 19, 2002, American Academy of Addiction Psychiatry, San Antonio, Texas

Presenter, Screening, motivational interviewing and brief intervention for patients with alcohol problems. October 21, 2002, Hanley-Hazelden Foundation, West Palm Beach, Florida

Course Director and Faculty Instructor, New strategies in treating opioid dependence: Buprenorphine Training, October 27, 2002, American Society of Addiction Medicine Review Course, Chicago, Illinois

Presenter, Connecticut Chapter of American Society of Addiction Medicine, Buprenorphine Treatment meeting: "The Nuts & Bolts", November 11, 2002, Connecticut Valley Hospital, Middletown, Connecticut

Faculty Instructor, Buprenorphine: An office-based treatment for opioid dependence, November 15, 2002, Tennessee Department of Health, Bureau of Alcohol and Drug Abuse Services, Nashville, Tennessee

Presenter, Screening, motivational interviewing and brief intervention for patients with alcohol problems. November 18, 2002, Hanley-Hazelden Foundation, West Palm Beach, Florida

Presenter, Addiction in the Primary Care Setting: Impact on Youth, Pregnant & Parenting Women and Families. December 3, 2002, Vermont Physician's Conference on Addiction Medicine, Vermont Department of Health and Vermont Medical Society, Stowe, Vermont

Faculty Instructor, Buprenorphine Training Session, December 13, 2002, American Academy of Addiction Psychiatry, Miami, Florida

Reviewer, Technical Review Panel, Buprenorphine Clinical Practice Guidelines, Convened by the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Department of Health and Human Services 2003

Presenter, Pharmacologic interventions for substance abuse, January 8, 2003, National Association of Drug Court Professionals, Juvenile and Family Drug Court Training Conference, Washington, DC
Medical Grand Rounds, Office-based treatment of opioid dependent patients, January 21, 2003, San Francisco General Hospital, San Francisco, California

Course Director and Faculty Instructor, Buprenorphine and office-based treatment of opioid dependence, January 22, 2003, American Society of Addiction Medicine, San Francisco, California

Chair, Buprenorphine Consensus Conference, March 7, 2003, American Academy of Addiction Psychiatry, Bethesda, Maryland

Presenter, Buprenorphine: The New Opioid Addiction Therapy, March 31, 2003, American Federation for AIDS Research 15th National HIV/AIDS Conference, Miami, Florida

Presenter, Buprenorphine and Office Based Treatment of Opioid Dependence, April 4, 2003, American Society of Addiction Medicine, Seattle, Washington

Presenter, American Association for the Treatment of Opioid Dependence Workshop, Buprenorphine and Office-Based Treatment of Opioid Dependence, April 12, 2003, Washington, DC

Presenter, American Association for the Treatment of Opioid Dependence Workshop, Implementing Opiate Dependence Treatment in Office-Based Settings, April 14, 2003, Washington, DC

Presenter, American Association for the Treatment of Opioid Dependence Workshop, Buprenorphine Part I: The Clinical Perspective, April 14, 2003, Washington, DC

Faculty Instructor, Buprenorphine Training Course, American Psychiatric Association Annual Conference, May 21, 2003, San Francisco, California

Presenter, Join Together of Boston University, Reducing substance abuse: The expanding role of primary care, June 5, 2003, Chicago, Illinois

Faculty Instructor, Using Buprenorphine in Office-Based Treatment of Opioid Dependence, Vermont Consortium for Addiction Training, June 28, 2003, Burlington, Vermont

Presenter, Buprenorphine Physician Training Seminar, Second Annual New England School for the Treatment of Opioid Dependence, Medical aspects of treatment of opiate dependence, July 11, 2003, Salve Regina University, Newport, Rhode Island

Faculty Instructor, Office-based Treatment of Opioid Dependence with Buprenorphine, The Maryland State Medical Society, September 6, 2003, Baltimore, Maryland

Faculty Instructor, Wisconsin Society of Addiction Medicine Buprenorphine Course, September 20, 2003, Milwaukee, Wisconsin

Presenter, Faculty Training Program on Addiction, Hanley-Hazelden, Screening and Brief Intervention and Motivational Interviewing, September 29, 2003, West Palm Beach, Florida

Presenter, Office-Based Treatment of Opiate Addiction: Buprenorphine, Massachusetts Psychiatry Society, October 4, 2003, Newton, Massachusetts

Presenter, Office-Based Treatment of Opioid Dependence with Buprenorphine, Addiction Medicine: Evidence-Based Treatment Strategies, Harvard University, October 24, 2003, Boston, Massachusetts

Moderator, Drug-Seeking Behavior and the Transition to Dependence. State of the Art in Addiction Medicine Conference, American Society of Addiction Medicine, October 30, 2003, Washington, DC

Moderator, Dilemmas in Translating Science to Service - Why Aren't Physicians Prescribing Buprenorphine? State of the Art in Addiction Medicine Conference, American Society of Addiction Medicine, November 1, 2003, Washington, DC

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, November 2, 2003, Washington, DC

Presenter, Office-Based Treatment of Opioid Dependence with Buprenorphine, American Society of Addiction Medicine, Massachusetts Medical Society, November 22, 2003, Waltham, Massachusetts

Faculty Instructor, Office-Based Treatment of Opioid Dependence with Buprenorphine. Case Western Reserve University, American Society of Addiction Medicine, December 6, 2003, Cleveland, Ohio

Course Director, Buprenorphine in Office-Based Treatment of Opioid Dependence, Institute for Professional Development in the Addictions, American Society of Addiction Medicine, January 24-25, 2004, New York, New York

New Treatment Strategies for Opioids, New England Regional Meeting of the American Society of Addiction Medicine, January 29, 2004, Southington, Connecticut

Participant, Buprenorphine in the Primary HIV Care Setting, Forum for Collaborative HIV Research, George Washington University, February 3, 2004, Washington, DC

Faculty instructor, Office-Based Treatment of Opioid Dependence with Buprenorphine, Maryland State Medical Society, American Society of Addiction Medicine, February 7, 2004, Baltimore, Maryland

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, February 8, 2004, Atlanta, Georgia

Presenter, Substance Use Disorders in HIV-seropositive Patients: Impact and New Treatment Strategies, International AIDS Society-USA, March 17, 2004, New York, New York

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, Medical Scientific Conference, American Society of Addiction Medicine, April 25, 2004, Washington, DC

Course Director, Office-Based Treatment of Prescription Opioid and Heroin Dependent Patients, Society of General Internal Medicine, May 12-13, 2004, Chicago, Illinois

Presenter, Update in Alcohol, Tobacco and Other Drug Abuse for Generalist Physicians, Society of General Internal Medicine, May 13, 2004, Chicago, Illinois

Presenter, Chronic Disease and Substance Abuse: New Research Initiatives, Society of General Internal Medicine, May 14, 2004, Chicago, Illinois

Plenary Presenter, Buprenorphine 101: Basic Background and Framework, Buprenorphine in the Primary HIV Care Setting, The George Washington University Forum for Collaborative HIV Research, June 3-4, 2004, Washington, DC

Course Director, Buprenorphine and Office-based Treatment of Opioid Dependence, NY AIDS Institute, American Society of Addiction Medicine, Institute for Professional Development in the Addictions, June 10, 2004, Batavia, New York

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, June 12, 2004, New Haven, Connecticut

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, July 31, 2004, St. Louis, Missouri

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, August 5, 2004, New York, New York

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Association for the Treatment of Opioid Dependence (AATOD) Conference, October 16-20, 2004, Orlando, Florida

Presenter, American Society of Addiction Medicine Review Course in Addiction Medicine, November 5, 2004, Toronto, Canada

Plenary Presenter, 28th Annual Association for Medical Education and Research in Substance Abuse (AMERSA) National Conference, November 11-13, 2004, Washington, DC

Presenter, Faculty Training Program on Addiction, Hanley-Hazelden, Screening and Brief Intervention and Motivational Interviewing, December 6, 2004, West Palm Beach, Florida

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, December 11, 2004, Tampa, Florida

Presenter, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Osteopathic Academy of Addiction Medicine, January 29, 2005, Providence, Rhode Island

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, February 9, 2005, Grand Blanc, Michigan

Presenter, Implementation of Buprenorphine, New England Regional American Society of Addiction Medicine (ASAM), March 9, 2005, Plantsville, Connecticut

Presenter, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Psychiatric Association, March 19, 2005, New Haven, Connecticut

Co-Chair, Buprenorphine Summit 2005, Center for Substance Abuse Treatment/SAMHSA and National Institute on Drug Abuse, April 11-12, 2005, Rockville, Maryland

Presenter, Prescription Drug Abuse: Science to Practice, American Society of Addiction Medicine,

April 16, 2005, Dallas, Texas

Co-Chair, NIDA Symposium, Prescription Drug Abuse: Science to Practice, American Society of Addiction Medicine, April 16, 2005, Dallas, Texas

Presenter, Policy Plenary Session: Policy Barriers to Office-Based Treatment with Buprenorphine, American Society of Addiction Medicine, April 16, 2005, Dallas, Texas

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, April 17, 2005, Dallas, Texas

Presenter, Buprenorphine and Office Based Treatment of Opioid Dependence, American Psychiatric Association, June 4, 2005, Baltimore, Maryland

Co-Chair, Emerging Drug Problems in South Florida, NIDA Blending Conference, June 7, 2005, Miami, Florida

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, September 9, 2005, Saratoga Springs, New York

Presenter, Addiction Medicine Symposium, Alaska Regional Hospital, October 13-14, 2005, Anchorage, Alaska

Presenter, Recognition and Treatment of Alcohol Problems, Reid Hospital and Health Care Services, January 10, 2006, Richmond, Indiana

Grand Rounds, Office-Based Treatment of Opioid Dependent Patients with Buprenorphine, Reid Hospital and Health Care Services, January 11, 2006, Richmond, Indiana

Course Director, Buprenorphine and Office-Based Treatment of Opioid Dependence, American Society of Addiction Medicine, April 22, 2006, Atlanta, GA

Coordinator, Substance Abuse Task Force, 29th Annual Society of General Internal Medicine Meeting, April 28, 2006, Los Angeles, CA

International Presentations

Presenter, Office-based treatment of opioid dependence, European Opiate Addiction Treatment (EUROPAD) Conference, May 14, 2002, Oslo, Norway

Presenter, Buprenorphine adherence in office-based treatment of opioid dependence, European Opiate Addiction Treatment (EUROPAD) Conference, May 15, 2002, Oslo, Norway

Presenter, Workshop on Novel pharmacological and non-pharmacological treatments in substance abuse, Institute for Cognitive Science Studies, Tehran University of Medical Sciences, and United Nations Office of Drug and Crime, July 28-30, 2003, Tehran, Iran

Presenter, 11th International Conference "Aids, Cancer and Related Problems", "Integrated Prevention for Drug Users: Yale Reports on HIV, Hepatitis and Drug Use Prevention" October 6-10, 2003, St. Petersburg, Russia

Presenter, Treatment of Addictive Diseases: Opioid and Alcohol Dependence, August 7, 2004, Nairobi, Kenya

Presenter, Treatment of Addictive Diseases: Opioid and Alcohol Dependence, August 12, 2004, Mombasa, Kenya

Participant, WHO 1st Consultation on Technical Guidelines for Treatment of Opioid Dependence, November 1-4, 2005, Geneva, Switzerland.

Professional Service (selected)

Editorial Board, *Substance Abuse*

Computer Software

The Gold Standard, 1988, Iatrogenic Software. Instructional software for a medical student course in clinical epidemiology.

Honors and Awards

Henry Christian Award for most meritorious abstract (Health Services Research: Impact on Clinical Care), Annual Meeting of the American Federation for Medical Research, Washington, D.C., April 25-27, 1997.

Physician Scientist, Substance Abuse Center, Yale University School of Medicine, New Haven, Connecticut. 1997-2002.

Best Abstract Award, National Conference of the Association for Medical Education and Research in Substance Abuse, Alexandria, Virginia. November 4-6, 1999.

Clinical Investigator Award, Society of General Internal Medicine, New England Region, Providence, Rhode Island. March 31, 2000.

Semi-Finalist, Best Abstract Award, National Conference of the Association for Medical Education and Research in Substance Abuse, Alexandria, Virginia. November 2-4, 2000.

Robert Wood Johnson Generalist Physician Faculty Scholar, Yale University School of Medicine, New Haven, CT, 2001-Present

Nyswander/Dole Award, American Association for the Treatment of Opioid Dependence, Atlanta, Georgia, April 25, 2006.

Journal Review

Journal of Clinical Epidemiology
Addiction
Alcohol Health and Research World
Drug and Alcohol Dependence
The American Journal of Medicine
Annals of Internal Medicine
Substance Abuse
JAMA
Clinical Pharmacology and Therapeutics
New England Journal of Medicine

Teaching Activities

1994- Attending Physician, Yale-New Haven Hospital, Internal
Medicine Service and Primary Care Center

1994-1995 Chief Resident, Yale-New Haven Hospital and West Haven VAMC

- 1994-1995 Facilitator, Doctor/Patient Encounter (history and physical diagnosis course for first and second year medical students), Multicultural Module, Yale University School of Medicine
- 1995-1998 Clinical Tutor, Doctor/Patient Encounter (history and physical diagnosis course for first and second year medical students), Yale University School of Medicine
- 1995- Facilitator, Student-Faculty Rounds, Ambulatory Component of the Internal Medicine Clerkship (discussion of ambulatory topics with third year medical students), Yale University School of Medicine
- 1997- Case Conference Leader, "Alcohol Problems", Ambulatory Component of the Internal Medicine Clerkship, Yale University School of Medicine
- 1999-2003 Course Director, Clinical Epidemiology and Biostatistics, Physician Associate Program, Yale University School of Medicine
- 1999-2000 Instructor, Curriculum in Clinical Research, Department of Internal Medicine, Yale University School of Medicine
- 2000- Course Co-Director, Principles of Clinical Research and Seminars in Clinical Investigation, Investigative Medicine Program, Yale University School of Medicine

Committees

- 1994-5 Ambulatory Education Committee, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- 1994-5 Clinical Education Committee, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- 1994-5 Intern Selection Committee, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- 1994- Task Force on Substance Abuse, Society of General Internal Medicine
- 1994-7 Work Group on Intensity of Services for Alcohol Withdrawal, American Society of Addiction Medicine
- 1999-2002 Abstract Selection Committee, Association for Medical Education and Research in Substance Abuse (AMERSA)
- 1999-2000 Medical Maintenance Consensus Panel, Convened for the Office of Pharmacologic and Alternative Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Department of Health and Human Services
- 1999-2000 Methadone Advisory Committee, Connecticut Department of Mental Health and Addiction Services
- 2000-2001 Buprenorphine Physician Training Project, Generalist Physician Curriculum Panel, Convened by the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Department of Health and Human Services
- 2000-2002 Chair, Abstract Selection Committee, Association for Medical Education and Research in Substance Abuse (AMERSA)

- 2000-2002 Strategic Planning Advisory Committee, Health Resources Service Administration-
Association for Medical Education and Research in Substance Abuse Interdisciplinary
Faculty Development Program
- 2000-2001 Research Abstract Review Subcommittee, Society of General Internal Medicine
National
Meeting
- 2001 Participant, Alcohol problems among emergency department patients: Research on
identification and intervention, March 19-21, 2001, Convened by Centers for Disease
Control and Prevention, Arlington, Virginia
- 2001- Member, Medications Development Committee, American Society of Addiction
Medicine
- 2001- Chair, Buprenorphine Subcommittee, Medications Development Committee, American
Society of Addiction Medicine
- 2002 Member, Review Course Planning Committee, American Society of Addiction Medicine
- 2002- Co-Chair, Substance Abuse Task Force, Society of General Internal Medicine
- 2002 Member, Program Committee, Annual Medical-Scientific Conference, American Society
of Addiction Medicine
- 2003 Member, Treatment Expert Panel, Convened by The Office of National Drug Control
Policy (ONDCP) January 28, 2003, Washington, DC
- 2003 Member, Ad Hoc Work Group on Office-Based Treatment of Opioid Dependence,
American Society of Addiction Medicine
- 2003 Participant, Buprenorphine-Highly Active Antiretroviral Treatment Clinical Study
Planning Group, National Institute on Drug Abuse (NIDA), October 31, 2003, Rockville,
MD
- 2004- Member, White House Office of National Drug Control Policy (ONDCP), Drug Control
Research, Data, and Evaluation Advisory Committee, Washington, DC
- 2004 Member, Buprenorphine Task Force, College on Problems of Drug Dependence (CPDD)
- 2004- Member, Core Faculty, International AIDS Society - USA
- 2005 Member, Review Course Planning Committee, American Society of Addiction Medicine
- 2004- Member, Medical Education Council, American Society of Addiction Medicine
- 2004 Member, Expert Panel Leadership Conference on Medical Education in Substance Abuse,
Office of National Drug Control Policy, December 1-2, 2004, Washington, DC
- 2005- Member, Expert Panel, National Institute on Drug Abuse Primary Care
Physician Outreach (PCPO) Project
- 2005- Member, Technical Guideline Development Group (TDG), Department of Mental Health
and Substance Abuse, World Health Organization, Geneva, Switzerland

Licensure and Certification

1992 National Board of Medical Examiners, #408861
1994 American Board of Internal Medicine, Internal Medicine, #156826
1994 Connecticut State Medical License, #033601
2001 American Society of Addiction Medicine, #078335-00

Membership -Professional Societies

Society of General Internal Medicine
Society for Clinical Epidemiology and Health Care Research
Association for Medical Education and Research in Substance Abuse (AMERSA)
American Society of Addiction Medicine
American Association for the Treatment of Opioid Dependence (AATOD)
College on Problems of Drug Dependence (CPDD)

Rev 6-26-06